The tumor suppressor PTEN is mutated in a high percentage of human cancers, and is implicated in pathways regulating cell growth, proliferation, survival, and migration. Despite significant advances, our understanding of its mechanisms of action remains incomplete. We have used a high-throughput proteomic immunoblotting approach to identify proteins whose expression levels are modulated by PTEN. Out of over 800 proteins screened, 22 proteins showed significant changes in expression. Five proteins that exhibited two-fold or greater changes in expression level were further characterized. AKAP121 and G3BP expression was reduced, while dihydrofolate reductase (DHFR), Rap1 and RCC1 expression was elevated in response to PTEN expression in a PTEN-null T-cell leukemia line. The phosphatase activity of PTEN was required for these effects. However, direct inhibition of PI-3 Kinase could mimic PTEN in modulating expression of DHFR, G3BP, Rap1 and RCC1, but not AKAP121. Real-time PCR showed that the effects of PTEN were primarily post-transcriptional, and would not have been revealed by mRNA-based screens. We conclude from these data that PTEN can modulate the expression level of a number of different proteins. The identified proteins have the potential to serve as previously unrecognized effectors of PTEN, and suggest the existence of additional complexity in the modes by which PTEN can regulate cellular biology.
Introduction
PTEN (phosphatase and tensin homologue deleted in chromosome 10), also known as MMAC1 (mutated in multiple advanced cancer) and TEP1 (TGFb-regulated and epithelial cell-enriched phosphatase), is a tumor suppressor gene located on chromosome 10q23 (Li and Sun, 1997; Steck et al., 1997) . Loss of heterozygosity and somatic mutations of PTEN that lead to partial or complete loss of the lipid phosphatase activity of PTEN have been documented in an increasing variety of malignant tumors at both advanced and early stages (Sulis and Parsons, 2003) . Germline mutations of PTEN cause four rare autosomal-dominant syndromes that have similar clinical features: Cowden Syndrome, Lhermitte-Duclos disease, Bannayan-Zonana syndrome, and Proteus syndrome. These diseases share the tendency to develop hamartomas and other benign tumors, while Cowden Syndrome is additionally associated with the development of malignant tumors (Pilarski and Eng, 2004) . Mice heterozygous for PTEN-inactivating mutations also have a high incidence of spontaneous tumors of various histological origins, accompanied by impaired Fasmediated apoptosis and the development of a polyclonal autoimmune disorder. Complete inactivation of the gene is lethal early in development, with stem cells from these mice displaying increased in vivo and in vitro proliferation and an impaired ability to differentiate (Di Cristofano et al., 1998 .
Functionally, PTEN is a phosphatase that can act on protein and lipid substrates (Myers et al., 1997) . However, its lipid phosphatase activity, resulting in the specific hydrolysis of phosphate from the 3 0 -OH of phosphatidylinositol-3,4,5-trisphosphate (PIP 3 ), is generally accepted as accounting for its ability to suppress tumor formation (Maehama and Dixon, 1998; Myers et al., 1998) . PTEN opposes the activity of the lipid kinase, PI-3 kinase (PI3K), and thereby maintains basal PIP 3 at a low level. Cells that lack PTEN have elevated levels of PIP 3 even in the resting state. PIP 3 is a potent second messenger that binds a subset of proteins containing pleckstrin-homology (PH) domains to elicit cellular behaviors that favor oncogenesis. Among the most important of these PH-domain-containing proteins is the serine/threonine kinase Akt (also known as protein kinase B). This kinase modulates the activities of multiple proteins involved in regulating cell migration, survival, growth, and proliferation, and many studies have suggested that the ability of PTEN to act as a tumor suppressor rests largely or entirely on its ability to regulate the activity of Akt (Sulis and Parsons, 2003) . Nonetheless, there are indications that we have yet to fully understand all of the mechanisms by which PTEN acts to regulate cellular behavior (Waite and Eng, 2002) . These include observations where it is the protein phosphatase activity, rather than the lipid phosphatase activity, that is relevant for PTEN function. For example, in some cell types, the negative regulatory effect of PTEN on cell migration appears to be mediated by direct dephosphorylation of focal adhesion kinase (FAK) and of Shc. Also, the decline in cyclin D1 expression that accompanies PTEN expression can also be mediated by the protein phosphatase activity of PTEN. Finally, PTEN has also been noted to partition into the nucleus, and reduced nuclear localization of PTEN has been observed in neoplastic tissues. Taken together, these findings suggest that there are likely to be many as yet unidentified targets of PTEN, and underscore the need for a better understanding of the normal regulatory mechanisms of PTEN.
Toward this end, we have used a proteomic approach in order to uncover changes in the protein expression pattern in the Jurkat T-cell leukemia line that occur upon restored PTEN expression. These cells are normally PTEN-negative (Sakai et al., 1998; Shan et al., 2000; Xu et al., 2002) . Restoration of PTEN expression in these cells by the use of a drug-inducible expression system results in a substantially reduced rate of proliferation as a result of uniformly slowed progression through all stages of the cell cycle without induction of cell cycle arrest or significant apoptosis (Seminario et al., 2003) . This response to PTEN restoration seems to be unique among PTEN-null tumors and is more in keeping with the ability of normal PTEN-expressing cells to grow and proliferate, making this system uniquely useful for studying the role of PTEN in regulating normal cellular functions. Using this model system, we have conducted a high-throughput immunoblotting approach to identify proteins that exhibit significant changes in their expression level in response to changes in PTEN expression level. Several proteins are identified whose expression levels were modulated by PTEN. These proteins, and the pathways that they participate in, may represent additional downstream effectors of PTEN.
Results

Protein expression pattern in PTEN-inducible Jurkat T cells obtained by PowerBlott screening
In order to gain leads into currently unrecognized biochemical pathways that are regulated by PTEN, a high-throughput immunoblotting approach was used to concurrently measure relative changes in the expression level of more than 800 different proteins (using all of the mAbs then available for use in the BD PowerBlot assay). The Jurkat T-cell leukemia line does not express PTEN, and we have previously described the generation of two independent Jurkat clones, PIJ-12 (PTENinducible Jurkat, clone 12) and PIJ-17, that express PTEN in response to induction with doxycyline (Dox) (Seminario et al., 2003) . A concurrently generated control Jurkat cell line, Con-18, does not express PTEN in response to Dox. Two separate screens were carried out as described in Materials and methods section, comparing either Dox-treated PIJ-12 or PIJ-17 with Dox-treated Con18 cells.
Prior to screening, PTEN expression and function were confirmed in the Dox-treated PIJ cells by Western blotting for PTEN and phospho-Akt (Figure 1 ). Akt is constitutively phosphorylated and activated in normal Jurkat T cells as a result of PIP 3 accumulation due to unopposed basal PI3K activity. Clearly, Dox treatment induced PTEN expression in both PIJ-12 and PIJ-17 cells, but not in Con18 cells, and PTEN expression was associated with de-phosphorylation of Akt. It should also be noted that even in the absence of Dox treatment there was a low level of PTEN expression in the PIJ-12 and PIJ-17 cells due to the leakiness of the promoter, which can be appreciated in longer film exposures. This low level of PTEN expression is partially effective in opposing PI3K activity, as evidenced by decreased Akt phosphorylation. The very low signal seen in the Con18 cells at long exposure is not PTEN, but a nonspecific band recognized by the secondary antibody (data not shown). From these data, it is clear that, by comparing Dox-treated Con18 cells to Dox-treated PIJ cells, one can compare a PTEN-null Jurkat cell line to a Jurkat cell line that expresses functional levels of PTEN.
Of the more than 800 proteins screened, 48 were scored as showing evidence for PTEN-dependent changes of 1.5-fold or greater by the criteria elaborated in Materials and methods section (Table 1) . In 30 of these, both PIJ lines showed comparable effects of PTEN on expression. The remaining 18 proteins scored as positives exhibited significant PTEN-dependent expression differences in one of the two clones, while the protein was either not detected or was not screened for in the other PTEN-expressing clone. Of the 48 proteins scored positive via PowerBlott, 42 proteins were selected for confirmatory screening (Table 1) . Cellular lysates from PIJ-12, PIJ-17, and Con18 cells, all treated with or without Dox, were immunoblotted with 42 of the same antibodies used in the initial large-scale screen. Eight antibodies failed to detect the target protein, 12 revealed no consistent PTEN-dependent change, two gave the opposite of what was observed in the initial screen, and 20 gave results that were in agreement with the initial screen (Table 1) . In order to better assess the degree of agreement between the results of the re-screening experiment and the initial PowerBlott screen, the immunoblots were quantitated by scanning laser densitometry. The fold difference in the expression levels of the proteins in the two Dox-treated PIJ cells as compared to the Doxtreated Con18 cells were averaged together (Table 2 , second column). This is the same parameter that was measured in the PowerBlott screen, and was used to assess whether or not the re-screen confirmed the PowerBlott results. The difference in protein expression level between the uninduced PIJ cells and the uninduced Con18 cellsreflecting the effect of the low level of PTEN expression in PIJ cells prior to induction -was also determined (Table 2 , first column), as was the difference in protein expression levels before and after Dox induction of the PIJ cells (Table 2 , third column). For this last parameter, the Con18 data were used to correct for any effect attributable to Dox alone. This latter measure is interesting, as it compares the protein expression level at the low level (promoter leak) of PTEN expression, which is phenotypically silent, to the higher, induced expression level, which results in slowed cellular growth and proliferation (Seminario et al., 2003) . Using these two measurements, the 22 proteins that exhibited measurable changes in expression in response to PTEN can be placed into one of five different groups (Table 2 and Figure 2 ). Group 1 proteins exhibited increased expression in response to low-level PTEN expression (without Dox treatment) and did not respond appreciably to further increases in PTEN expression. This group includes Annexin I (gene name: ANXA1), ASAP1 (ARF GTPase-activating protein 1, gene name: DDEF1), Dok2 (docking protein 2, gene name: DOK2), PKCy (protein kinase C-theta, gene name: PRKCQ), Pyk2 (proline-rich tyrosine kinase 2, gene name: PTK2B), Rac1 (ras-related C3 botulinum toxin substrate, gene name: RAC1), and SHP-1 (Src homology domain 2 phosphatase-1, gene name: PTPN6). There is only one protein in group 2, RCC1 (regulator of chromosomal condensation-1, gene name: CHC1), which is characterized by basally higher expression in the PIJ cells, and an additional increase in expression upon Dox induction. Group 3 proteins responded to PTEN induction with increased expression. DHFR (dihydrofolate reductase, gene name: DHFR), DNA ligase III (gene name: LIG3), Rap1 (gene name: RAP1A), and SRPK2 (serine/arginine-rich proteinspecific kinase 2, gene name: SRPK2) are members of this group. Group 4 includes ABP-280 (actin-binding protein-280, filamin, gene name: FLNA), AKAP121 (A-kinase anchor protein, gene name: AKAP1), CDK2 (cyclin-dependent kinase 2, gene name: CDK2), Cyclin Table 2) .
Protein expression changes following transient expression of PTEN
Given that our primary interest in screening for proteins that exhibit changes in expression in response to PTEN is to reveal novel pathways by which PTEN may act in its capacity as a tumor suppressor, and, since we have found no differences in cellular growth or proliferation between uninduced PIJ and uninduced Con18 cells (Seminario et al., 2003) , the remainder of our analyses were limited to proteins from groups 2 to 4. Six proteins in these groups exhibited a twofold or greater change in expression level in response to Dox induction. Five of these proteins, AKAP121, DHFR, G3BP, Rap1, and RCC1, were selected for further study. ABP-280 was not studied further due to difficulty in routinely detecting this protein.
To ensure that the expression changes observed in the initial screens were reproducible and not artifacts of clonal selection, Jurkat T cells were transiently transfected with either control vector, wildtype PTEN, or phosphatase-dead PTEN (C124S), and changes in the expression level of AKAP121, DHFR, G3BP, Rap1, and RCC1 were measured by Western blotting (Figure 3) . In each case, transient transfection gave similar results as those observed in the Doxinducible system, and required the phosphatase activity of PTEN. The effect of PTEN on the expression of these proteins also showed dose dependency, with higher amounts of PTEN plasmid giving greater changes in expression ( Figure 3 ). The levels of PTEN expression and lipid phosphatase activity were confirmed by PTEN and phospho-Akt Western blotting, respectively. Western blotting for ZAP-70 was carried out to confirm equal loading of the lanes.
Variable sensitivity of PTEN-targeted proteins to direct inhibition of PI3K
To test if PTEN is acting through its ability to inhibit signaling through the PI3K/Akt axis in affecting expression of our target proteins, we determined whether two commonly used inhibitors of PI3K, wortmannin and LY294002, could mimic the effects of PTEN on the expression levels of AKAP121, DHFR, G3BP, Rap1, and RCC1 ( Figure 4 ). Both drugs inhibited PI3K activity, as indicated by reduced basal serine-473 phosphorylation of Akt, although clearly the wortmannin treatment was more effective. Both PI3K inhibitors could mimic the effects of PTEN on the expression levels of G3BP, Rap1, and RCC1, indicating that PTEN is acting through a PI3K-dependent pathway to affect the expression level of these proteins. Oddly, LY294002 could increase DHFR expression levels (mimicking PTEN), while wortmannin could not, even though wortmannin treatment gave a more complete block in PI3K activity, as assessed by the extent of reduction in the basal Akt phosphorylation. Interestingly, neither wortmannin nor LY294002 could reduce AKAP121 expression, suggesting the possibility of a PI3K-independent pathway for PTEN in modulating AKAP121 levels. PTEN effect on protein expression level is largely independent of transcription rate PTEN can affect gene expression via multiple pathways, including p53, NF-kB, NFAT, AP-1, and forkhead transcription factors (Downward, 2004) . In order to assess whether PTEN might be affecting the protein expression levels of AKAP121, G3BP, DHRF, Rap1, or RCC1 via changes in the rate of gene transcription, we used real-time PCR to measure changes in the steadystate level of the mRNAs encoding these proteins. This analysis was carried out on cells that were treated under conditions that were identical to those that elicited the changes in protein expression reported above. Surprisingly, there was little correlation between the effect of Dox-induced PTEN expression at the protein and mRNA levels ( Table 3 ). The three-fold basal increase in RCC1 protein level induced by the leak level of PTEN in the uninduced PIJ cells, however, was correlated with a 2.35-fold increase in message level.
Entry of T cells into the cell cycle is associated with reduced PTEN expression and increased G3BP expression
We have previously noted that primary human T cells subjected to mitogenic stimuli exhibit greatly reduced PTEN expression (Figure 5a ; Wange, unpublished observation) over the course of 3 days. Western blotting these same cell lysates for G3BP showed that G3BP expression levels moved reciprocally to the PTEN expression levels (Figure 5a ), consistent with our data showing that forced expression of PTEN is associated with reduced expression of G3BP in the Jurkat T-cell line. Furthermore, when overexpressed in primary human T cells, G3BP augments the ability of mitogenic stimulation through the T-cell antigen receptor (TCR) and CD28 to increase the rate of cell cycle entry, as measured by [ 3 H]thymidine uptake.
Discussion
As an initial step towards identifying alternative effector pathways for PTEN, we have used a proteomic approach based on high-throughput immunoblotting to study changes in the expression pattern of specific proteins in response to changes in PTEN expression level. More than 800 different proteins were screened. From this initial screen and subsequent confirmatory screens, we have identified 22 proteins that consistently respond to increased PTEN expression by changes in their own expression level. These proteins showed a remarkable variety of responses and sensitivities to the þ T cells were transfected with a G3BP expression plasmid and stimulated with either mAb to CD3, mAb to CD3 þ PMA or mAb to CD3 þ CD28 24 h after transfection. Of the 22 proteins identified, six consistently showed two-fold or greater changes in protein expression in response to PTEN levels that are associated with reduced growth and proliferation (Seminario et al., 2003) . An additional study of five of these proteins established that the magnitude of the change in expression was dependent on the concentration of PTEN, and required the phosphatase activity of PTEN. Four of these proteins (DHFR, G3BP, Rap1, and RCC1) showed comparable responses to both PTEN expression and pharmacologic inhibition of PI3K, while AKAP121 was not affected by PI3K inhibition. It is notable though that increased DHFR expression was only detected in experiments using LY294002, but not wortmannin, even though LY294002 is the less effective of the two inhibitors. The basis of this discrepancy is currently unclear. One possibility is that LY294002 could be acting via inhibition of a kinase other than PI3K in order to affect DHFR expression level. Consistent with this possibility, it has recently been shown that LY294002, but not wortmannin, is equally potent as an inhibitor of both CK2 (formerly known as casein kinase II) and PI3K (Davies et al., 2000) . Clearly, the fact that CK2 has well over 300 identified substrates and pleiotropic effects on mRNA translation and protein stability (Pinna, 2002) complicates the interpretation that the effects of LY294002 on DHFR are due to inhibition of PI3K, especially since wortmannin does not yield similar results as LY294002, even while eliciting a more complete inhibition of PI3K. It is also formally possible, however, that LY294002 is correctly revealing a role for PI3K in PTEN-initiated changes in DHFR expression, which is not revealed by wortmannin. This could potentially result from the different chemical stabilities of the two inhibitors, and how they were employed in our study. Owing to the reported rapid decomposition of wortmannin in aqueous solutions (Powis et al., 1994) , fresh wortmannin was added to the cells every 2 h. This could theoretically permit accumulation of significant levels of the breakdown products of wortmannin catabolism, which may serendipitously block the effects of PI3K inhibition on DHFR expression level. However, to the best of our knowledge, the ability of wortmannin breakdown products to affect cellular biochemistry has never been demonstrated.
In an attempt to further address the issue of whether PTEN is acting independently of PI3K to affect the expression levels of AKAP121 and DHFR, the ability of the G129E mutant of PTEN was assessed for its ability to affect expression levels of these proteins; however, the mutant PTEN could not mimic the effects of wild-type PTEN on either of these proteins (data not shown). We would caution, however, that failure of G129E-PTEN to mimic wild-type PTEN is not a sufficient criterion for rejecting the hypothesis of PTEN acting through dephosphorylation of a protein substrate. While this mutant allele of PTEN has been widely used as a lipid phosphatase-dead/protein phosphatase-live allele, this is an imprecise characterization of this mutant. It should be noted that retention of activity has only been measured against a highly heterogeneous artificial protein substrate, polyGluTyr(4 : 1), which is a highly phosphorylated mixture of random polypeptide sequences with, on average, four residues of glutamate for every residue of tyrosine (Myers et al., 1997 (Myers et al., , 1998 Furnari et al., 1998; Ramaswamy et al., 1999) . In most of these studies (Furnari et al., 1998; Myers et al., 1998; Ramaswamy et al., 1999) G129E had less than wild-type activity towards pGluTyr(4 : 1), and in one study (Ramaswamy et al., 1999) the activity was as low as 30% of wild-type. Most importantly, none of these studies have established retention of the Ser/Thr phosphatase activity of PTEN in the G129E mutant.
Thus, from our data and the forgoing discussion, we suggest that it is possible, but by no means conclusive, that PTEN is acting through one or more PI3K-independent pathways to affect the protein expression levels of AKAP121 and DHFR. There is only little precedent to guide speculation on how the PI3K-independent pathway may be regulated. Both FAK and Shc have been shown to serve as direct substrates in some cell systems (Tamura et al., 1999) , although these results have proven to be controversial. More recent studies have implicated a role for PTEN in regulating PDGF receptor tyrosine phosphorylation (Mahimainathan and Choudhury, 2004) , as well as the autodephosphorylation of PTEN itself (Raftopoulou et al., 2004) . It remains to be determined whether any of these proteins or a currently unrecognized protein represents the relevant, putative proteinaceous PTEN substrates for affecting AKAP121 or DHFR expression.
Substantially more precedent is available to guide consideration of how the three proteins that are clearly regulated by PTEN in a PI3K-dependent manner (G3BP, Rap1, and RCC1) may be regulated. PTEN can alter protein expression at multiple levels via its ability to oppose PI3K and inhibit Akt activation. At the transcriptional level, Akt affects the activity of multiple transcription factors, including p53, NF-kB, NFAT, AP-1, and Forkead family members (Downward, 2004) . At the post-transcriptional level, Akt activates mTOR by phosphorylating and inactivating a negative regulator of mTOR, tuberin/TSC2, thereby increasing the rate of 7-methylguanosine cap-dependent and 5' terminal oligopyrimidine tract (TOP)-dependent translation initiation via S6-kinase activation and relaxed inhibition of eIF4E (Richardson et al., 2004) . At the post-translational level, Akt has recently been shown to directly regulate the ubiquitination and proteasomal degradation of a subset of its substrates (Plas and Thompson, 2003) . Akt is also a negative regulator of the serine/threonine kinase GSK3 (Jope and Johnson, 2004) . GSK3 targets several proteins, such as b-catenin and c-Myc, for proteolytic cleavage. The balance between PI3K and PTEN has also been shown to regulate the expression level of SKP2, a ubiquitin E3 ligase that acts as a component of the SCF ligase. The expression levels of PTEN and SKP2 are inversely related (Mamillapalli et al., 2001) . However, SKP2 appears to be highly selective and only targets a handful of proteins involved in cell cycle regulation, such as p27
Kip1 and p21 CIP1 (Reed, 2003) , and so is unlikely to play a significant role in regulating the expression levels of our target proteins.
Of the five proteins characterized, only RCC1 seems to be affected by PTEN via transcription-level regulation, with a 2.4-fold increase in message, compared to a threefold increase in protein, measured in uninduced PIJ cells, compared to uninduced Con18 cells. Notably, even for RCC1, transcriptional regulation does not contribute toward the further twofold increase in protein expression that occurs in PIJ in response to high levels of PTEN expression. The other proteins are presumably regulated via changes in translation rate or protein stability, although the precise mechanism remains to be uncovered. Increased GSK3 activity in response to PTEN-mediated Akt inactivation does not appear to play a role however, since a pharmacologic inhibitor of GSK3 did not reverse the effect of PTEN (Huang and Wange, unpublished data). Understanding the mechanisms by which PTEN regulates the expression levels of the five target proteins identified in this study is the subject of ongoing investigation.
Further investigation will also be required before anything definitive can be concluded about the roles that the identified PTEN-sensitive proteins may play in mediating the pleiotropic pathways that are subject to regulation by PTEN. It is interesting to note, however, that eight of the 20 proteins identified (ABP-280, Annexin I, ASAP, Dok2, Pyk2, Rac-1, Rap-1, and SHP-1) are involved to various degrees in events that regulate cell adhesion and migration, events that are strongly affected by PTEN. PTEN also caused small, but reproducible downmodulations of Cyclins A and B, and CDK2, consistent with the delayed cell cycle progression that is associated with PTEN expression in these cells, and our previous data showing reductions in mRNA levels for Cyclins A and B upon PTEN expression in Jurkat T cells (Seminario et al., 2003) .
Perhaps two of the more interesting proteins to be identified in the screen are G3BP and RCC1. G3BP is interesting from the standpoint that, while it is not an oncogene, its expression level is low in most normal cells, but is upregulated in multiple primary cancers and cancer cell lines (Guitard et al., 2001) . When overexpressed in NIH3T3 cells, G3BP promotes S-phase entry (Guitard et al., 2001) . Dedifferentiation and proliferation of retinal pigment epithelial cells placed in culture is associated with increased expression of G3BP mRNA (Kociok et al., 1999) . We have also found that, while G3BP is highly expressed in Jurkat T cells (derived from an acute T lymphocytic leukemia (Schneider et al., 1977) ), its expression is very low in normal human peripheral T cells, but is upregulated in response to mitogenic stimuli that concordantly downmodulate PTEN expression. Furthermore, overexpression of G3BP in primary human T cells augments mitogenically stimulated cell cycle entry. How G3BP acts to modulate S-phase entry remains unclear, but several interesting activities have been associated with this protein. G3BP was initially cloned on the basis of its ability to specifically bind to the SH3 domain of Ras-GAP and thereby modulates signaling events downstream of Ras (Parker et al., 1996; Pazman et al., 2000) ; it is an RNAbinding protein with intrinsic endonuclease activity that cleaves mRNA in vitro in a phosphorylation-dependent manner (Gallouzi et al., 1998; Tourriere et al., 2001) , and it has RNA and DNA helicase activities (identical to human DNA helicase VIII) (Costa et al., 1999) . Thus, it is conceivable that the increased G3BP expression, that our data predicts, would accompany loss of PTEN expression, and could contribute towards oncogenesis.
The apparent link between PTEN expression and RCC1 expression is particularly intriguing. RCC1 is a chromatin-localized guanine nucleotide exchange factor for the small molecular weight G protein, Ran. RCC1 is therefore a critical component of the system that maintains a high GTP-bound Ran gradient across the nuclear envelope. This gradient is required for normal nuclear/cytoplasmic transport of macromolecules (Moore, 2001) . Interestingly, Yamaguchi and Newport (2003) have recently shown that nuclear Ran-GTP is also required in order to inhibit the inappropriate formation of prereplication complexes, and thereby limiting replication to a single round per cell division. Indeed, these same investigators found that lowering Ran-GTP in the nucleus results in DNA re-replication. Data presented here show that loss of PTEN expression leads to reduced RCC1 expression, which could in turn lower levels of Ran-GTP, and induce a predisposition towards DNA re-replication and increased genomic instability. RCC1 is also required for coordinating the onset of mitosis with S-phase completion in mammalian cells (Moore, 2001) . Therefore, maintenance of RCC1 expression levels may represent another important tumor suppressor mechanism of PTEN.
In summary, we report on the first use of a highthroughput immunoblotting proteomic approach to investigate changes in protein expression as a consequence of re-expression of PTEN in a PTEN-null cancer line. This approach holds a theoretical advantage over gene expression screening techniques (e.g. cDNA array or serial analysis of gene expression (SAGE)), in that it can capture changes in protein expression that arise from changes at any level of regulation. Indeed, the five proteins that exhibited the biggest changes upon PTEN expression in our screen would not have been revealed by mRNA screening. PTEN had pleiotropic effects on the expression levels of specific proteins, with some proteins showing increased expression and others decreased expression. While additional studies will have to be carried out before it can be determined whether any of these proteins serve as bona fide effectors of PTEN, the recovery of proteins like G3BP, whose expression is upregulated in tumor cells, and RCC1, which plays a regulatory role in DNA prereplication complex licensing, is certainly suggestive.
Materials and methods
Cells, plasmids, and antibodies
PTEN-expressing clones PIJ-12 and PIJ-17 and the control clone Con18, and their culture conditions have been described (Seminario et al., 2003) . Human leukemic Jurkat T cells (ATCC) were maintained as described (Shan et al., 2000) . The constructs pSRa-Flag-PTEN wt, pSRa-Flag-PTEN C/S (C124S), and Flag-PTEN G/E (G129E) have been described (Shan et al., 2000) . The pCDEF3-Myc-G3BP construct was made by PCR amplification of human G3BP cDNA, a gift from Dr J Tazi (Centre National de la Recherche Scientifique, Montpellier, France) using primers that insert an in-frame N-terminal Myc tag into the PCR product, which was subsequently cloned into the pCDEF3 vector. Polyclonal anti-human PTEN was obtained from Cascade Biosciences; polyclonal anti-phospho-Akt (P-Ser472/473/474) was from BD Biosciences; anti-ZAP-70 antisera have been previously described (Wange et al., 1995) . All of the other antibodies used in the initial and confirmatory Western blot screens were monoclonal antibodies from BD Biosciences.
PowerBlott analysis
PTEN expression was induced in PIJ-12 and -17 cells by treatment with Dox as previously described (Seminario et al., 2003) . Briefly, cells maintained between culture densities of 5 Â 10 5 -1 Â 10 6 cells/ml were treated with Dox at a final concentration of 1 mg/ml. After 2 days, Dox-treated Con18, PIJ-12, and PIJ-17 were washed in PBS, and proteins were extracted as per Becton Dickinson's protocol. In short, cells were disrupted in boiling lysis buffer (10 mM Tris, pH 7.4, 1 mM sodium orthovanadate, and 1% SDS), briefly heated to 95-1001C for 30 s, and cellular DNA sheared by sonication. Protein concentration of the lysates was measured by BCA reagent (Pierce), and lysates were adjusted to a final concentration of 1 mg/ml in 2 Â electrophoresis buffer (125 mM Tris, pH 6.8, 4% SDS, 10% glycerol, 0.006% bromophenol blue, and 2% b-mercaptoethanol). Protein samples (300 mg) were loaded into single gel-wide lanes and run on six identical preparative, 4-15% polyacrylamide gradient SDS-PAGE gels (Criterion, Bio-Rad) and transferred to Immobilon-P nylon membrane (Millipore). Following 1 h of incubating in blocking buffer (LI-COR), the membranes were placed in a Western blotting manifold (Immunetics) that isolated 40 longitudinal channels across the membrane. Into each of the resulting identical 240 channels, a monoclonal antibody cocktail of 1-8 mAbs was added and allowed to hybridize for 1 h at 371C. For the screening of Dox-induced PIJ-17 cells vs Dox-treated Con18 cells, a total of 823 different mAbs were used (Supplementary Table 1 ). For the screening of Dox-induced PIJ-12 cells vs Dox-treated Con18 cells, a total of 861 different mAbs were used (Supplementary Table 2 ). The difference reflects the addition of new mAbs to the screen by Becton Dickinson during the several months that elapsed between the two different screens. The blots were then removed from the manifolds, washed, and allowed to hybridize for 30 min at 371C with secondary goat anti-mouse antibody conjugated to Alexa-fluor 680 (Molecular Probes). The membrane was subsequently washed, dried, and scanned using the Odyssey Infrared Imaging System (LI-COR), and individual protein bands were quantitated and normalized to the aggregate signal from all other valid protein bands on the membrane (Supplementary Tables  3 and 4 ). Molecular weight standards were created by the addition of a particular antibody cocktail to lane 40 of each gel: P190 glued (190 kDa), Adaptin beta (106 kDa), STAT-3 (92 kDa), PTP1D (72 kDa), Mek-2 (46 kDa), RACK-1 (36 kDa), GRB-2 (24 kDa), and Rap2 (21 kDa).
Each sample was analysed in three separate runs as above. For each clone, proteins that exhibited changes in expression of 1.5-fold or greater, as averaged over the three runs, and which showed consistency between the runs, were considered further. These candidates were then checked against the results with the other clone. mAbs that gave inconsistent results in the two different clones were not considered further. Candidate proteins that exhibited the same pattern in both clones were considered to be positive for this assay. Furthermore, proteins exhibiting a 1.5-fold change, which were either undetectable or not tested for in the other clone, were also considered to be positive.
Expectedly, there are technical limitations to this technique. The use of the mAb cocktail, which permits multiplexed protein expression level screening, while using only a small number of replicately loaded gels/membranes, limits the ability to optimize the mAb titer to the cell type analysed, and also introduces complications of interpretation due to mAb crossreactivity at molecular weights associated with the targets of other mAbs present in the cocktail. This can lead to false positives and false negatives, which can be identified in rescreening experiments using the identified mAb alone under optimal conditions for that combination of the mAb and cell type.
Western blotting and transient transfection
PIJ-12, -17, and Con18 cells were treated with Dox as above. After 2 days treatment, þ /ÀDox-treated cells were harvested, washed once in PBS, and lysates were made in lysis buffer (20 mM HEPES (pH 7.4), 1% Trition X-100, 50 mM bglycerophosphate, 2 mM EGTA, 10 mM sodium fluoride, 10% glycerol, supplemented with 1 mM sodium orthovanadate, 10 mg/ml of leupeptin and aprotinin, and 100 mg/ml of 4-(2-aminoethyl) bezenesulfonyl fluoride). After 30 min incubation on ice, post-nuclear lysates were prepared by a 10 min centrifugation at 41C and 21 000g. The lysates were denatured by heating to 951C in Nu-PAGE sample buffer, subjected to electrophoresis on 4-12% Nu-PAGE gradient gels, and transferred to a nitrocellulose membrane according to the manufacturer's instructions (Invitrogen). Concentrations for blotting antibodies varied according to the manufacturer's recommendations. Transferred proteins were detected by immunoblot using Enhanced Chemiluminescence (Renaissance, NEN) according to the manufacturer's instructions. In some experiments, immunoblots were quantitated by scanning laser densitometry using NIH Image software. Transient transfection of Jurkat T cells was achieved by electroporation as previously described (Shan et al., 2000) . After transfection the cells were cultured overnight in complete medium prior to use.
PI3K inhibitor treatment
In some experiments, Jurkat T cells were treated with either 200 nM of the PI3K inhibitor wortmannin (Calbiochem) or 25 mM LY294002 (Calbiochem) at 371C. LY294002 was added as a single bolus of drug, while wortmannin was added to the medium every 2 h, out to 12 h, in order to compensate for the rapid decomposition of this drug (Powis et al., 1994) . Cells were harvested and whole-cell lysates were prepared at the indicated time points.
Real-time RT-PCR
PIJ-12, -17, and Con18 cells were treated þ /ÀDox as above. Total RNAs were isolated by RNeasy Mini kit (Qiagen) according to manufacturer's protocol. In all, 2 mg of total RNA from each sample was used to generate cDNA using the Taqman Reverse Transcription Reagents (PE Applied Biosystems). The SYBR Green assay performed on the GeneAmp 5700 Sequence Detection System (PE Applied Biosystems) was used for measuring the relative levels of the RT-PCR products. Primers for five candidate genes (AKAP121, DHFR, G3BP, Rap1, and RCC1) were designed to cross intron-exon boundaries to ensure that the PCR products measured were generated from cDNA templates, not genomic DNA. The gene bank accession numbers and primer sequences from 5 0 to 3 0 for the five candidate genes and the control gene (GAPDH) are: AKAP121 (X97335), forward primer 5 0 -CAACCCTAAGA AGGTCGACCTC-3 0 , and reverse 5 0 -GCAGTGCCAGTGAA GGCAATG-3 0 ; DHFR (J00140), forward 5 0 -CTGGTTC TCCATTCCTGAGAAG-3 0 , and reverse 5 0 -GCCACCAAC TATCCAGACCATG-3 0 ; G3BP (U32519), forward 5 0 -GAG CAAGGTGACATTGAACCC-3 0 , and reverse 5 0 -CCTG TTGCTAAGGACTTTCTG-3 0 ; Rap1 (NM_002884), forward 5 0 -GTGACCTGGAAGATGAGCGAG-3 0 , and reverse 5 0 -CTAGAGCAGCAGACATGATTTC-3 0 ; RCC1 (X06130), forward 5 0 -GGCTTGGTGCTGACACTAGGC-3 0 , and reverse 5 0 -CCTCCACTGATGTGTCCCTTC-3 0 ; and GAPDH (NM_002046), forward 5 0 -GGA AGG TGA AGG TCG GAG TC-3 0 , and reverse 5 0 -GAA GAT GGT GAT GGG ATT TC-3 0 . Each PCR reaction was optimized to ensure that a single band of the appropriate length (150-300 bp) was amplified and that no bands corresponding to genomic DNA amplification or primer-dimer pairs were present. The PCR cycling conditions were performed for all of the samples as follows: 2 min at 501C for AmpErase UNG incubation; 10 min at 951C for AmpliTaq Gold activation; and 40 cycles for the melting (951C, 15 s) and annealing/extension (601C for 1 min) steps. PCR reactions for each template were carried out in triplicate in one 96-well dish per gene-specific primer pair tested, including for the GAPDH control. The comparative CT method was used to quantitate the expression for each gene relative to the Con18 cell line, using GAPDH as a normalization control (Livak, 2004) .
Isolation of primary human CD4
þ T cells from peripheral blood and stimulation in vitro Human primary CD4 þ T cells were isolated from donor peripheral blood by negative immunomagnetic separation as previously reported (Weng et al., 1995; Liu et al., 2001) . For stimulation, cells were resuspended in RPMI 1640 medium supplemented with 10% FBS at a concentration of 2-5 Â 10 6 cells/ml, then mixed with mAbs to CD3 and CD28 immobilized on Dynal beads (Lake Success, NY, USA) at a 1 : 1 cell : bead ratio and were incubated for the indicated time points prior to harvest.
Transient transfection of primary CD4
þ T cells and proliferation assay 5 Â 10 6 purified human primary CD4 þ T cells were mixed with 5 mg of DNA and electroporated by Amaxa (Gaithersburg, MD, USA) according to the manufacturer's protocol. After 16-20 h incubation, these cells were resuspended to 1 Â 10 6 cells/ml, seeded to a density of 5 Â 10 4 cells/well in quadruplicate samples in a 96-well flat-bottom plate (Fisher, Morris Plains, NJ, USA) in 0.2 ml RPMI 1640 medium, and stimulated with anti-CD3 mAb or a combination of anti-CD3 and anti-CD28 mAbs on Dynal beads with or without 50 ng/ ml of PMA. Cells were incubated for 24 h, then 1 m Ci of [
